Year: 2023

Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 11,813,279 and 11,813,281 for Ampligen® titled “Compositions for cancer therapy and methods,” and “Methods for improving exercise tolerance in myalgic encephalomyelitis patients,” respectively. AIM Chief Executive Officer Thomas K. Equels stated: “Our ongoing effort to expand and solidify AIM’s global intellectual property estate is a foundational component of our development strategy for Ampligen. AIM’s expectation for Ampligen — both as a therapeutic for people suffering...

Astrotech’s proven AgLAB Maximum Value Process™ delivers 32% average increase in revenue AUSTIN, Texas, Nov. 27, 2023 (GLOBE NEWSWIRE) — via IBN – Astrotech Corporation (NASDAQ: ASTC) (“Astrotech” or the “Company”) and its wholly owned subsidiary, AgLAB, Inc., announce the presentation of the AgLAB Maximum Value ProcessTM (“MVPTM”) at MJBizCon. This process is a revolutionary process control system proven to increase the potency of ending-weight yields and increase revenue by an average of 32%. MVPTM uses AgLAB’s proprietary mass spectrometer and testing method to provide real-time data and feedback, allowing distillers to adjust the parameters (temperature, feed-rate, pressure) and optimize the quality and quantity of each batch of oil. MVPTM is the fastest and most accurate testing method...

Vancouver, B.C., Nov. 27, 2023 (GLOBE NEWSWIRE) — Forty Pillars Mining Corp. (CSE: PLLR) (the “Company” or “Forty Pillars”) announces that, further to its news release dated November 17, 2023, effective at the opening of trading on November 30, 2023 (the “Effective Date”) the common shares of the Company (the “Shares”) will commence trading on the Canadian Securities Exchange on a consolidated basis, with one post-consolidated Share outstanding for every three pre-consolidation Shares (the “Consolidation”). As a result of the Consolidation, on the Effective Date, a total of approximately 4,897,529 Shares will be issued and outstanding, subject to adjustments for rounding, with approximately 2,691,666 Shares reserved for issuance. No fractional shares will be issued. The number of post-consolidated Shares to be received will be...

Petah Tikvah, Israel, Nov. 27, 2023 (GLOBE NEWSWIRE) — SaverOne 2014 Ltd. (Nasdaq: SVRE, TASE: SVRE), a technology company specializing in transportation safety solutions, today announced that it has withdrawn its previously announced proposed underwritten public offering of securities due to market conditions. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About SaverOne SaverOne is a technology company engaged in the design, development and commercialization of OEM and aftermarket solutions and technologies, to lower the risk of, and prevent, vehicle...

BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) — Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is hosting a virtual fireside chat with thought leader Gary Schiller, MD, FACP, Professor of Medicine and Director of the Hematological Malignancy & Stem Cell Transplant Program at the David Geffen School of Medicine at University of California – Los Angeles. Dr. Schiller will discuss his experience working with patients in need of allogeneic stem cell transplant, as well as the patient journey from diagnosis to transplant, the decision-making process for donor source selection, and his experience with Omisirge® (omidubicel-onlv) since its FDA approval. A live question and answer session will follow the fireside chat. Details are as follows: Virtual Thought Leader Fireside Chat...

VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) — NINE MILE METALS LTD. (CSE: NINE, OTCQB: VMSXF, FSE: KQ9) (the “Company” or “Nine Mile”), discloses that it will update the proposed unsecured loan financing for proceeds of up to $500,000 that it announced in the Company’s news release on November 21, 2023, to an unsecured convertible loan financing (the “Convertible Loan”). The Convertible Loan financing will be for proceeds of up to $500,000. The Convertible Loans will have a term of 12 months from the closing (the “Maturity Date”) and bear interest at 15 per cent per annum, calculated and payable on the Maturity Date. Convertible Loan proceeds will be used for advancing the bulk sample program on the Nine Mile Brook project and general working capital. No bonus shares will be offered in connection with the Convertible...

– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life – – SpringWorks to host conference call tomorrow at 8:00 a.m. ET –A Media Snippet accompanying this announcement is available by clicking on this link. STAMFORD, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has approved OGSIVEO™ (nirogacestat), an oral gamma secretase inhibitor, for the treatment of adult patients with progressing desmoid tumors who require systemic treatment.1 The...